First controlled field trial of NexGard® against canine cordylobiasis

In this clinical trial, we evaluated the efficacy of a single oral administration of afoxolaner (NexGard®) in dogs naturally infested with Cordylobia anthropophaga under field conditions in Kenya. The treatment showed high efficacy, reaching 86.3% by day 15, 100% by day 30, and 95.3% by day 45, and was associated with a clear improvement in skin lesions, lymph node reaction, and overall clinical condition. This study provides the first controlled field evidence that afoxolaner is an effective therapeutic option against this zoonotic cause of furuncular myiasis in dogs and also suggests a possible indirect protective effect in puppies born to or nursing from treated bitches.